RO 0334649

Drug Profile

RO 0334649

Alternative Names: RO-033-4649

Latest Information Update: 19 Sep 2006

Price : $50

At a glance

  • Originator Roche Palo Alto LLC
  • Class Antivirals
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 19 Sep 2006 Discontinued - Phase-I for HIV infections treatment in USA (PO)
  • 27 Mar 2003 Phase-I clinical trials in HIV infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top